fig1

The use of targeted LNP/mRNA technology to generate functional, transient CAR T cells and treat cardiac injury <i>in vivo</i>

Figure 1. The molecular events showing the generation of transient FAPCAR T cells using CD5-targeted LNPs. Adapted from Rurik et al.[1]. LNPs: Lipid nanoparticles.

The Journal of Cardiovascular Aging

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/